November 29, 2012
Arena Pharmaceuticals (Nasdaq: ARNA ) is best known for its weight-loss drug, Belviq, which is slated to hit the U.S. market soon. Its main competition will be VIVUS' (Nasdaq: VVUS ) Qsymia, and a third biotech -- Orexigen Therapeutics (Nasdaq: OREX ) -- continues to work toward approval from the Food and Drug Administration for its obesity drug, Contrave.
Arena struck a deal last quarter with South Korean company Ildong to commercialize Belviq in South Korea. Arena is getting $5 million for the deal and will be entitled to more payouts if further milestones are reached.
Recently, Arena expanded its relationship with Ildong to include temanogrel, a drug in the early phases of development that will be aimed at treating arterial thrombosis. In this video, Motley Fool health care analysts Max Macaluso and David Williamson break down this news and discuss why it's too early for investors to start celebrating this deal.
When it comes to do-or-die business, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand new premium research report on Arena Pharmaceuticals, we walk investors through the must know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.